|  | Sacubitril/valsartan |       | Control |       | Risk Ratio |                    | Risk Ratio                                      |
|--|----------------------|-------|---------|-------|------------|--------------------|---|
| Study or Subgroup  | Events               | Total | Events  | Total | Weight     | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI                              |
| Fan TT 2019  | 5                    | 35    | 8       | 35    | 1.1%       | 0.63 [0.23, 1.72]  | •   |
| Li J 2019 (1)  | 17                   | 62    | 29      | 64    | 3.8%       | 0.61 [0.37, 0.98]  | <del></del>                                     |
| PARADIGM-HF 2014   | 537                  | 4187  | 658     | 4212  | 87.1%      | 0.82 [0.74, 0.91]  | <b>-</b>  |
| PIONEER-HF 2018  | 35                   | 440   | 61      | 441   | 8.1%       | 0.58 [0.39, 0.85]  | <del></del>                                     |
| Total (95% CI)   |                      | 4724  |         | 4752  | 100.0%     | 0.79 [0.72, 0.87]  | •   |
| Total events   | 594                  |       | 756     |       |            |                    |   |
| Heterogeneity: Chi <sup>2</sup> = 4.36, df = 3 (P = 0.22); $I^2$ = 31% |                      |       |         |       |            |                    | 05 07 1 15 2                                    |
| Test for overall effect: $Z = 4.63$ (P < 0.00001)                      |                      |       |         |       |            |                    | 0.5 0.7 1 1.5 2<br>Sacubitril/valsartan Control |